多肽聚合纳米药物在肿瘤靶向治疗中的研究进展  

Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy

作　　者：张莹瑄 陈文莉[1] 陈红宇 畅立圣 杨柳[1] ZHANG Yingxuan;CHEN Wenli;CHEN Hongyu;CHANG Lisheng;YANG Liu(Department of Oncology,Baoshan Branch,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201999,China)

机构地区：[1]上海中医药大学附属曙光医院宝山分院肿瘤一科,上海201999

出　　处：《上海中医药大学学报》2022年第S01期291-295,共5页Academic Journal of Shanghai University of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81904013);中国博士后科学基金资助项目(2021M700548);上海市自然科学基金项目(19zr143800);上海市科委中医引导类项目(19401933100);上海市科委医学创新研究专项项目(21Y11922200);上海中医药大学附属曙光医院宝山分院国家自然科学基金培育项目(GZRPY-201801)

摘　　要：肿瘤组织由于肿瘤微环境、生物屏障等特点,化疗、免疫、中药等药物难以靶向渗透破坏肿瘤遗传物质。多肽聚合纳米药物具有易组装、可降解、靶向性等特点,由多肽聚合纳米药物介导的递送系统已成为肿瘤靶向性释药的主要研究方向。通过概述了近年来多肽纳米药物利用纳米药物递送系统多靶点结合、响应,对肿瘤靶向性释放,提高化疗、免疫、中药等抗肿瘤药物精准渗透疗效,降低口服吸收难溶性及毒副反应的研究进展,该领域也将成为未来抗肿瘤药物研究的主要发展方向。Due to the characteristics of tumor microenvironment and biological barrier,chemotherapy,immunity,traditional Chinese medicine and other drugs are difficult to penetrate and destroy tumor genetic material.Polypeptide polymerized nanodrugs have the characteristics of easy assembly,degradability and targeting,and the delivery system mediated by polypeptide polymerized nanodrugs has become the main research direction of tumor targeted drug release.This paper summarizes the recent progress of polypeptide nanodrugs that use multi-target combination and response of nanodrug delivery system,to tumor targeted release,improve the precise penetration curative efficacy of anti-tumor drugs such as chemotherapy,immunity and traditional Chinese medicine,and reduce oral absorption insoluble,toxic and side effects.This field will also become the main development direction of antitumor drug research in the future.

关 键 词：纳米颗粒 多肽 纳米药物递送系统 肿瘤 靶向治疗 

分 类 号：R943[医药卫生—药剂学]